Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PAVE 100: Multiclade HIV-1 DNA Plasmid Vaccine Followed by Adenoviral Vector Vaccine in HIV Uninfected Persons
NCT00498056Phase 2Withdrawn
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Modality
- Viral Vector Vaccines, DNA Vaccines
01
Overview
A Phase 2 trial of VRC-HIVDNA016-00-VP, VRC-HIVADV014-00-VP in human immunodeficiency virus infection (HIV), sponsored by National Institute of Allergy and Infectious Diseases. Status: withdrawn.
02
Drugs
VRC-HIVDNA016-00-VPVRC-HIVADV014-00-VP
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00498056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00498056.